Skip to content

MBX Biosciences, Inc. MBX Capital investments accrued but not yet paid

Capital investments accrued but not yet paid at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$608K

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.3B+475%
Enterprise value$2.26B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s capital investments accrued but not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s capital investments accrued but not yet paid?
MBX Biosciences, Inc. (MBX) reported capital investments accrued but not yet paid of $24K in Q1 2026.
How has MBX Biosciences, Inc.'s capital investments accrued but not yet paid changed year-over-year?
MBX Biosciences, Inc.'s capital investments accrued but not yet paid decreased by 95.2% year-over-year, from $502K to $24K.